Moreover, the signature of anti-tumor immunity elicited by VG161 is more robust than both VG160 and VG-VEC (VG160 backbone expressing GM-CSF) based on transcriptome sequencing data and differences in IFN-γ production and MHC molecule expression in CT26 tumor-bearing mice treated with each respective OV (Figure 10). The gene discussed is IFNG; the disease is neoplasm.